Could this vaccine stop the 'Kissing Disease' and its Long-Term risks?
NCT ID NCT05683834
First seen Nov 21, 2025 · Last updated May 08, 2026 · Updated 21 times
Summary
This study tested a new vaccine designed to prevent Epstein-Barr virus (EBV) infection, which causes mononucleosis and is linked to certain cancers and autoimmune diseases. The trial involved 25 healthy adults aged 18 to 25 who had never had EBV. Participants received either the vaccine or a placebo, and researchers monitored their immune response and safety for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.